Here's what we'll cover
Here's what we'll cover
Wegovy and Trulicity are both GLP-1 receptor agonists, but they represent different generations of the same drug class, approved for different purposes, with meaningfully different efficacy profiles. Most people searching this comparison are already on Trulicity for Type 2 diabetes and wondering whether something newer and stronger would be worth switching to.
The short answer is that semaglutide (Wegovy) is the more potent molecule on virtually every measure. The longer answer is that potency is not the only thing that matters.
What Each Drug Is Approved For
Wegovy (semaglutide, Novo Nordisk) is FDA approved for:
- Chronic weight management in adults and adolescents aged 12 and older with obesity or overweight with at least one weight related condition
- Reducing the risk of major cardiovascular events in adults with established heart disease and obesity or overweight
- Noncirrhotic MASH with liver fibrosis, under accelerated approval
Trulicity (dulaglutide, Eli Lilly) is FDA approved for:
- Type 2 diabetes in adults and pediatric patients aged 10 and older, as an adjunct to diet and exercise
- Reducing the risk of major cardiovascular events in adults with Type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors
Notice the key difference: Trulicity's cardiovascular indication requires a Type 2 diabetes diagnosis. Wegovy's does not. And Trulicity has no weight management indication at all.
| Factor | Wegovy (semaglutide) | Trulicity (dulaglutide) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA initial approval | 2021 (weight management) | 2014 (Type 2 diabetes) |
| Approved for weight loss | Yes | No |
| Approved for Type 2 diabetes | As Ozempic (separate brand) | Yes |
| Cardiovascular risk reduction | Yes (SELECT trial, includes patients without diabetes) | Yes (REWIND trial, requires Type 2 diabetes) |
| MASH indication | Yes (accelerated approval) | No |
| Available forms | Injection and oral tablet | Injection only |
| Dose range | 0.25 mg to 2.4 mg weekly (injection); up to 25 mg daily (tablet) | 0.75 mg to 4.5 mg weekly |
The Molecules: Same Class, Different Potency
Both are GLP-1 receptor agonists, meaning they mimic the same gut hormone. The difference is in how effectively they do it.
Semaglutide was engineered with modifications that give it a longer half life and stronger receptor binding than earlier GLP-1 drugs. This translates to more pronounced appetite suppression, greater weight loss, and stronger glucose control at therapeutic doses.
Dulaglutide was designed as a fusion protein that pairs a GLP-1 analog with an immunoglobulin fragment. This extends its duration of action to enable once weekly dosing, but the overall receptor activation is less potent than semaglutide.
In the SUSTAIN-7 trial, semaglutide 0.5 mg and 1.0 mg (Ozempic doses, not Wegovy doses) were compared head to head against dulaglutide 0.75 mg and 1.5 mg in patients with Type 2 diabetes. Semaglutide produced significantly greater A1C reduction and weight loss at both dose comparisons. The weight difference was approximately 2 to 4 kg more with semaglutide over 40 weeks.
That trial used lower semaglutide doses than Wegovy's 2.4 mg maintenance dose. At Wegovy dosing, the efficacy gap widens further.
Cardiovascular Protection: Both Have It, With a Key Difference
Both drugs have demonstrated cardiovascular risk reduction in large outcome trials, but the populations studied were different.
Trulicity's REWIND trial enrolled adults with Type 2 diabetes, including patients with and without established cardiovascular disease. It showed a 12% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) with dulaglutide versus placebo.
Wegovy's SELECT trial enrolled adults with established cardiovascular disease and obesity or overweight, specifically excluding patients with diabetes. It showed a 20% reduction in the same composite endpoint with semaglutide versus placebo.
The practical implication: if you have Type 2 diabetes with cardiovascular risk, both drugs offer protection. If you have cardiovascular disease with obesity but without diabetes, only Wegovy has been specifically studied and approved for that scenario.
No waiting list. No insurance needed.
Frequently Asked Questions
Is Trulicity approved for weight loss?
No. Trulicity is FDA approved for Type 2 diabetes and cardiovascular risk reduction in adults with Type 2 diabetes. It is not approved for weight management.
Is Wegovy more effective than Trulicity?
Semaglutide (the molecule in Wegovy and Ozempic) has outperformed dulaglutide (Trulicity) on both A1C reduction and weight loss in head to head trials. The difference is clinically meaningful.
Is Trulicity easier to get insurance coverage for than Wegovy?
A diabetes diagnosis typically makes Trulicity easier to get covered, since most plans include it as a standard formulary option. Wegovy for weight management faces the same category exclusion issue that affects other weight loss drugs.
Can I switch from Trulicity to Wegovy?
This is a physician decision, but you would not start at an equivalent dose. You would begin Wegovy titration at 0.25 mg and escalate over 16 weeks, regardless of your Trulicity dose.
Does Trulicity have fewer side effects than Wegovy?
Trulicity has substantially lower rates of nausea, diarrhea, vomiting, and constipation than Wegovy. If GI tolerability has been a problem for you, this difference matters.
Which one is better for heart protection?
Both carry FDA approved cardiovascular risk reduction, but through different trials (REWIND for Trulicity, SELECT for Wegovy). Wegovy's indication also covers patients without diabetes, while Trulicity's is specific to Type 2 diabetes.
Dosing: Different Ranges, Different Starting Points
| Dosing Detail | Wegovy (semaglutide) | Trulicity (dulaglutide) |
|---|---|---|
| Starting dose | 0.25 mg weekly (injection); 1.5 mg daily (tablet) | 0.75 mg weekly |
| Escalation schedule | Every 4 weeks through 5 steps (injection) | Increase to 1.5 mg after 4 weeks, then optional 1.5 mg increments every 4 weeks |
| Maintenance dose | 2.4 mg weekly (injection); 25 mg daily (tablet) | 1.5 mg to 4.5 mg weekly |
| Time to maintenance | 16 weeks (injection); 12 weeks (tablet) | 4 weeks minimum, up to 12 weeks at highest dose |
| Available forms | Prefilled pen, oral tablet | Prefilled pen only |
Trulicity reaches its therapeutic dose faster because the titration range is narrower. Wegovy's longer escalation reflects its higher potency and the need to manage GI tolerability during the ramp up. If you are switching from Trulicity to Wegovy, you restart titration from 0.25 mg regardless of your Trulicity dose.
Use Cases: Which Drug Fits Which Situation
You are on Trulicity for diabetes and want more weight loss. Switching to a newer GLP-1 (semaglutide via Ozempic) or a dual agonist (tirzepatide via Mounjaro) will likely produce better results on both glucose and weight. The SURPASS-2 trial showed tirzepatide outperforming semaglutide on both A1C and weight, and the SUSTAIN trials showed semaglutide outperforming dulaglutide on both measures. Discuss with your physician whether the stronger efficacy justifies the higher GI side effect rates and the insurance logistics of switching.
You want a weight loss medication and do not have diabetes. Trulicity is not an option. It has no weight management indication. Wegovy and Zepbound are the on label choices.
You have Type 2 diabetes with established cardiovascular disease. Both drugs offer cardiovascular protection, but through different trials. Trulicity's REWIND trial covered diabetes patients specifically. Wegovy's SELECT trial covered patients with and without diabetes. If cardiovascular protection is the primary goal, either is defensible, but Wegovy's data is more recent and showed a larger risk reduction (20% vs 12%).
You have struggled with GI side effects on other GLP-1 drugs. Trulicity's tolerability profile is meaningfully better. Nausea rates roughly half of Wegovy's, diarrhea roughly a third. A medication you tolerate consistently over years may deliver better outcomes than one you discontinue after two months.
You prefer not to inject. Wegovy is the only one of the two available as an oral tablet. Trulicity is injection only.
You want the simplest, most established option. Trulicity has been on the market since 2014, with over a decade of real world safety data. It is widely covered by insurance for diabetes. For patients whose primary need is reliable glucose control with modest weight loss and cardiovascular protection, Trulicity remains a solid, well understood choice.
Side Effects: Similar Types, Different Scale
Both drugs cause gastrointestinal side effects. Wegovy's rates are substantially higher, which reflects both its stronger efficacy and its higher effective dose.
| Side Effect | Wegovy (semaglutide 2.4 mg) | Trulicity (dulaglutide 1.5 mg) |
|---|---|---|
| Nausea | 44% | 12 to 21% |
| Diarrhea | 30% | 8 to 12% |
| Vomiting | 24% | 6 to 12% |
| Constipation | 24% | 4 to 6% |
| Stomach pain | 20% | 6 to 9% |
Wegovy's rates reflect the full titration period through the STEP trials. At maintenance doses, rates are lower but still meaningfully above Trulicity's. Both carry the same serious warnings: boxed warning about thyroid C cell tumors, risks of pancreatitis, gallbladder problems, kidney injury from dehydration, and allergic reactions.
Related Comparisons
- Ozempic vs Zepbound: Why You Are Comparing Two Drugs Approved for Different Things
- Wegovy vs Mounjaro: The Comparison That Changes Depending on Which Country You Are In
- Zepbound vs Trulicity: Two Very Different Generations of GLP-1
Medication guides: Wegovy, Trulicity, Ozempic, Zepbound
GLP-1.com can help. Compare top GLP-1 providers side by side, explore GLP-1 coupons and savings programs to reduce your monthly cost, and use our resources to go into your next doctor's appointment with better questions and clearer goals. Your health decisions should be driven by evidence and your own priorities. We are here to make sure you have both.
This content is for informational purposes only and is not medical advice. GLP-1.com does not sell or dispense medication. Consult a licensed physician regarding any treatment decision.